Rubedo Life Sciences

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biopharmaceutical company based in Mountain View, California, developing a broad portfolio of innovative therapies designed to target the cellular drivers of chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform integrates advanced single-cell multi-omics, AI with machine learning, and disease biology to identify pathological cell states and discover first-in-class therapeutics with precision activity across aging-related indications. Rubedo is pioneering a new class of senotherapeutics: Adaptive Senotherapeutics. These therapies are designed not only to selectively target and eliminate pathological senescent cells, but also to restore homeostasis and function in damaged yet rescuable cells. This state-dependent approach expands beyond traditional senolytics by addressing the dynamic biology of aging tissues. Our first clinical program, RLS-1496, is a first-in-class SenoAdaptive GPX4 modulator that has demonstrated clinical validation through target engagement, biomarker modulation, and early therapeutic activity in age-related dermatologic diseases. The program supports Rubedo’s broader mission to translate the biology of cellular senescence into disease-modifying medicines for dermatological, fibrotic, pulmonary, oncological, neurodegenerative, and other chronic disorders. Rubedo’s leadership team brings together pioneers in aging biology, chemistry, AI-enabled drug discovery, clinical development, and biotechnology commercialization, with deep experience spanning large pharma, academia, and biotech innovation.